From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lefamulin skeletal.svg
Clinical data
SynonymsBC 3781
ATC code
  • None
Legal status
Legal status
  • Investigational
CAS Number
PubChem CID
Chemical and physical data
Molar mass507.73 g·mol−1
3D model (JSmol)

Lefamulin is a pleuromutilin antibiotic that is being developed by Nabriva Therapeutics for the treatment of acute bacterial skin and skin-structure infections (ABSSSI).[1] It was granted fast track status by the US Food and Drug Administration in 2014. As of May 2016, it is in phase III clinical trials.[2]

Spectrum of activity[edit]

Lefamulin has in vitro activity against Streptococcus viridans, Moraxella catarrhalis, Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA), among other bacteria.[2][3]


  1. ^ Zeitlinger, M; Schwameis, R; Burian, A; Burian, B; Matzneller, P; Müller, M; Wicha, W. W.; Strickmann, D. B.; Prince, W (2016). "Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid". Journal of Antimicrobial Chemotherapy. 71 (4): 1022–6. doi:10.1093/jac/dkv442. PMID 26747098.
  2. ^ a b H. Spreitzer (23 May 2016). "Neue Wirkstoffe - Lefamulin". Österreichische Apothekerzeitung (in German) (11/2016).
  3. ^ Mendes, R. E.; Farrell, D. J.; Flamm, R. K.; Talbot, G. H.; Ivezic-Schoenfeld, Z; Paukner, S; Sader, H. S. (2016). "In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States". Antimicrobial Agents and Chemotherapy. 60: AAC.00627–16. doi:10.1128/AAC.00627-16. PMC 4914675. PMID 27161634.